July 23, 2018 12:12pm
CRSP (-$0.58 or -0.99%), EDIT (-$0.15 or -0.41%) and NTLA (-$0.13 or -0.41%) at Monday’s mid-day
After a continuous “shuffle” to the downside; investors aren't ignoring the latest concern about CRISPR-Cas9!
And, it ain’t over … back and forth in the day’s range
Reiterating, researchers found that using CRISPR-Cas9 to edit DNA in mouse cells and in a human differentiated cell line caused extensive unintended changes in DNA sequences that were relatively far away from the target DNA sequence. Those other unintended changes could potentially cause cancer or other diseases.
It's certainly concerning that using CRISPR-Cas9 could result in unintended DNA changes. This idea is akin to going into surgery for a tonsillectomy and ending up with one of your kidneys removed inadvertently. Not a good situation <MotleyFool>.
CRISPR-Cas9 had been touted as the biotech discovery of the century. CRISPR-Cas9 might have potential, but also comes with huge risks!
As I stated on Friday’s closing bell: “Gene editing companies are feeling the low digit trades and with only 1 to the upside (EDIT +$0.12). The “unanswered question is, “what happens to distant metastases even if CRISP rehoming cells successfully attack the original tumor?”
“Would you bet your life and your current portfolio on a mouse model; it’s always a game of “truth or consequences!”